NCT00000180

AIT-082 Phase 1B Study

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: —
• Sponsor: National Institute on Aging (NIA) · NIH
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals with neurological deficits. This study was a double-blind placebo-controlled safety study that was designed to study whether AIT-082 may delay age-related mental decline. Eight healthy older volunteers at two clinical sites were given single, weekly, rising doses of AIT-082 or placebo for 5 weeks; were tested for side effects and absorption; and underwent a battery of neuropsychological memory tests, including word and number recall tests.

Conditions

• Memory Disorders

Interventions

Type	Name	Description
DRUG	AIT-082

Timeline

• Primary completion: 2005-06-01
• Completion: 2005-06-01
• First posted: 1999-11-01
• Last updated: 2009-12-11

Locations

4 sites across 1 country: United States